GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Starpharma Holdings Ltd (ASX:SPL) » Definitions » PB Ratio

Starpharma Holdings (ASX:SPL) PB Ratio : 1.43 (As of May. 05, 2024)


View and export this data going back to 2000. Start your Free Trial

What is Starpharma Holdings PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-05-05), Starpharma Holdings's share price is A$0.12. Starpharma Holdings's Book Value per Share for the quarter that ended in Dec. 2023 was A$0.08. Hence, Starpharma Holdings's PB Ratio of today is 1.43.

Good Sign:

Starpharma Holdings Ltd stock PB Ratio (=1.43) is close to 10-year low of 1.41

The historical rank and industry rank for Starpharma Holdings's PB Ratio or its related term are showing as below:

ASX:SPL' s PB Ratio Range Over the Past 10 Years
Min: 1.41   Med: 6.63   Max: 28.1
Current: 1.43

During the past 13 years, Starpharma Holdings's highest PB Ratio was 28.10. The lowest was 1.41. And the median was 6.63.

ASX:SPL's PB Ratio is ranked better than
71.19% of 1312 companies
in the Biotechnology industry
Industry Median: 2.5 vs ASX:SPL: 1.43

During the past 12 months, Starpharma Holdings's average Book Value Per Share Growth Rate was -16.00% per year. During the past 3 years, the average Book Value Per Share Growth Rate was 0.40% per year. During the past 5 years, the average Book Value Per Share Growth Rate was -5.40% per year. During the past 10 years, the average Book Value Per Share Growth Rate was -3.30% per year.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Starpharma Holdings was 13.70% per year. The lowest was -31.60% per year. And the median was 0.05% per year.

Back to Basics: PB Ratio


Starpharma Holdings PB Ratio Historical Data

The historical data trend for Starpharma Holdings's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Starpharma Holdings PB Ratio Chart

Starpharma Holdings Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.93 13.39 9.77 6.27 3.65

Starpharma Holdings Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.93 6.27 5.50 3.65 2.02

Competitive Comparison of Starpharma Holdings's PB Ratio

For the Biotechnology subindustry, Starpharma Holdings's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Starpharma Holdings's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Starpharma Holdings's PB Ratio distribution charts can be found below:

* The bar in red indicates where Starpharma Holdings's PB Ratio falls into.



Starpharma Holdings PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Starpharma Holdings's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Dec. 2023)
=0.12/0.084
=1.43

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Starpharma Holdings  (ASX:SPL) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Starpharma Holdings PB Ratio Related Terms

Thank you for viewing the detailed overview of Starpharma Holdings's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Starpharma Holdings (ASX:SPL) Business Description

Traded in Other Exchanges
Address
4-6 Southampton Crescent, Abbotsford, Melbourne, VIC, AUS, 3067
Starpharma Holdings Ltd is an Australia-based company engaged in the research, development, and commercialization of dendrimer products for pharmaceutical, life science, and other applications. It focuses on the development of VivaGel for the management and prevention of bacterial vaginosis and as a condom coating and VIRALEZE an antiviral nasal spray.

Starpharma Holdings (ASX:SPL) Headlines

No Headlines